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Abstract 23 
Severe diabetes frequently induces skeletal muscle atrophy, and dystrophin disruption has 24 
been implicated in the pathogenesis of skeletal muscle atrophy. We hypothesized that the 25 
downregulation of dystrophin expression causes diabetic-induced muscle atrophy, and 26 
investigated whether dystrophin mRNA and protein levels are altered in the atrophic muscles 27 
of diabetic rats. Rats received a single intravenous injection of streptozotocin (STZ) (45 28 
mg/kg body weight). Slow-twitch soleus and fast-twitch extensor digitorum longus muscles 29 
were dissected from each rat 4 or 12 weeks after the STZ injection. The STZ group had 30 
significantly higher blood glucose levels and lower body weights than the control group. The 31 
relative muscle weight per body weight was also lower in the STZ group than in the control 32 
group, and these changes accompanied a reduction in glucose transporter 4. The 33 
phosphorylation of Akt Ser473 and p70 S6 kinase Thr389 was lower in the soleus and extensor 34 
digitorum longus muscles of the diabetic rats than in those of the control rats. In contrast, 35 
dystrophin mRNA and protein expression were higher in the muscles of the diabetic rats than 36 
in those of the control rats. A histochemical study showed that the localization of dystrophin 37 
did not differ between the muscles of the control and diabetic rats. Our data suggest that the 38 
downregulation of dystrophin is not a general characteristic associated with skeletal muscle in 39 
diabetes. 40 
 41 




成蛋白質の 1 つであるジストロフィンの欠損は骨格筋萎縮を誘発する。本研究では糖尿病性45 
筋萎縮の進行にはジストロフィン欠損が関与しているという仮説を立て、筋萎縮を呈するス46 
トレプトゾトシン（STZ）誘発性糖尿病モデル動物を用いて、萎縮骨格筋におけるジストロ47 
フィン mRNA およびタンパク発現量を測定した。8 週齢の雄性 Sprague-Dawly ラットに生理48 
食塩水に溶解した STZ（45 mg/kg body weight）を尾静脈投与した群を STZ群とし、生理食塩49 
水を投与した群を対照群とした。投与 4または 12週間後にヒラメ筋および長指伸筋を摘出す50 
るとともに血液を採取した。STZ 群では対照群に対し、血糖値の上昇および体重減少、体重51 
あたりのヒラメ筋および長指伸筋重量の低下が認められた。また筋萎縮に伴って glucose 52 
transporter 4タンパク発現量の減少が認められた。STZ群の萎縮骨格筋では対照群に比べ、Akt 53 





江川達郎、増田慎也、後藤勝正、林達也  59 
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Introduction 60 
Dystrophin is a structural protein that connects the cytoskeleton of a muscle fiber to the 61 
surrounding extracellular matrix through the cell membrane. Mutation of dystrophin disrupts 62 
the mechanical linkage and signaling pathway, resulting in membrane damage, necrosis, and 63 
eventual muscle atrophy 1). Dystrophin dysfunction is also implicated in muscle wasting of 64 
cancer cachexia 2, 3), which is associated with impaired insulin action in skeletal muscle 4). 65 
Poorly controlled diabetes affects protein metabolism 5) and induces skeletal muscle 66 
atrophy 6). Although several studies have shown that reduced protein synthesis contributes to 67 
it 7, 8), the precise mechanism of diabetic-induced muscle atrophy is not understood. Using 68 
streptozotocin (STZ)-induced diabetic rats, recent studies have demonstrated that reduced 69 
Akt/ mammalian target of rapamycin (mTOR) signaling is associated with diabetic-induced 70 
muscle atrophy 9). Risson et al. 10) showed that the inactivation of mTOR leads to advanced 71 
myopathy, with a strong reduction in the muscle dystrophin content. 72 
We hypothesized that the downregulation of dystrophin expression might be associated 73 
with diabetic-induced muscle atrophy. Thus, the primary purpose of this study was to 74 
examine the expression of dystrophin mRNA and protein in the atrophic muscles of 75 
STZ-induced diabetic rats. We also examined the changes in dystrophin localization in these 76 
rats by histochemical analysis.  77 
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Materials and methods 78 
Animals 79 
All protocols for animal use and euthanasia followed the Guiding Principles for the Care 80 
and Use of Animals in the Field of Physiological Sciences (Physiological Society of Japan), in 81 
accordance with international guidelines, and were approved by the Kyoto University 82 
Graduate School of Human and Environmental Studies. Male Sprague Dawley rats (8 weeks 83 
old) were housed in an animal room maintained at 22–24 °C on a 12:12-h light–dark cycle 84 
and were fed a standard laboratory diet and water ad libitum. 85 
 86 
STZ treatment 87 
Diabetes was induced with STZ (Sigma, St Louis, MO, USA). In brief, the animals 88 
received a single intravenous injection of STZ (45 mg/kg body weight) via the tail vein. The 89 
control animals received an equivalent volume of saline. Blood glucose levels were measured 90 
using the glucose oxidase method, with an automated blood glucose analyzer (GluTestAce, 91 
Sanwa Chemical Research Institute Co., Inc., Nagoya, Japan). Diabetes was defined as a 92 
nonfasting glucose level of ≥ 300 mg/dl. 93 
 94 
Muscle sampling 95 
The animals were anesthetized with pentobarbital sodium (50 mg/kg body weight) and 96 
killed 4 or 12 weeks after the STZ or saline injection. The soleus (SOL) and extensor 97 
digitorum longus (EDL) muscles were dissected from each rat, weighed, immediately frozen 98 
in liquid nitrogen, and stored at –80 °C for immunoblotting and Real-time RT-PCR analysis. 99 
Some muscles were frozen in 2-methylbutane cooled with solid CO2 and stored at –80 °C for 100 
histochemical analysis. 101 
 102 
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Immunoblotting analysis 103 
Total protein from muscles were extracted as we described previously 11, 12) and subjected 104 
to immunoblotting analyses. Blots were incubated with rabbit-anti Akt Ser473 (9271, Cell 105 
Signaling Technology, Danvers, MA), rabbit-anti Akt (9272, Cell Signaling), rabbit-anti p70 106 
S6 kinase (p70S6K) Thr389 (9205, Cell Signaling Technology, Danvers, MA), rabbit-anti 107 
p70S6K (9202, Cell Signaling), rabbit anti-glucose transporter (GLUT) 4 (AB1346; 108 
Chemicon, Temecula, CA, USA), mouse anti-dystrophin antibody (MAB1692; Chemicon). 109 
The signal was detected by using ECL reagents (GE Healthcare, Buckinghamshire, UK). The 110 
intensity of the signals was quantified using MultiAnalyst software (Bio-Rad Laboratories, 111 
Berkeley, CA, USA). Every blot was duplicated and the mean value was adopted for each 112 
sample. 113 
 114 
Real-time RT-PCR analysis 115 
Real-time RT-PCR analysis was performed according to Yasuhara et al. 13). Briefly, total 116 
RNA was extracted from muscles using the miRNeasy Mini kit (Qiagen, Hiden, Germany). 117 
Samples were reverse-transcribed using PrimeScript RT Master Mix (Perfect Real Time) for 118 
mRNA (Takara Bio, Otsu, Japan). Synthesized cDNA was applied to real-time reverse 119 
transcription-PCR (Thermal Cycler Dice Real Time System IIMRQ, Takara Bio) using Takara 120 
SYBR Premix Ex Taq II for mRNA, and analyzed with Takara Thermal Cycler Dice Real 121 
Time System Software Ver. 4.00. To normalize the amount of total RNA present in each 122 
reaction, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA for mRNA was used 123 
as an internal standard. The primers were designed by using the Takara Bio Perfect Real Time 124 
Support System (Takara Bio). Primers used for detection of rat cDNA were as follows: 125 
Dystrophin, 5’-AGGCCAAGTGTAACATCTGTAAGGA-3’ (forward) and 126 
5’-CCTTAGCAACTCGGCCAGAA-3’ (reverse); GAPDH, 127 
 7 
5’-GGCACAGTCAAGGCTGAGAATG-3’ (forward) and 128 
5’-ATGGTGGTGAAGACGCCAGTA-3’ (reverse). 129 
 130 
Histochemical analysis 131 
The histochemical analyses used to detect dystrophin were as we described previously 11). 132 
The sections were incubated with mouse anti-dystrophin antibody (MAB1692; Chemicon), 133 
and stained with 3,3’-diaminobenzidine. Histochemical analysis was performed using a 134 
microscope (Optiphot-2, Nikon, Tokyo, Japan) with a charge-coupled device camera and a 135 
computerized image processing system (Image/J 1.36b). To calculate the mean cross-sectional 136 
area of the muscle fibers, 100-150 fibers were randomly picked up from each of the muscles. 137 
 138 
Statistical analysis 139 
The results are presented as means ± SE. Means were compared with two-way ANOVA, 140 
followed by a post hoc comparison with Scheffé’s test as appropriate. P < 0.05 was considered 141 
statistically significant.  142 
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Results 143 
Glucose levels, body weight, muscle weight, GLUT4 levels 144 
The STZ group had significantly higher blood glucose levels and lower body weights 145 
than the control group at 4 and 12 weeks (Table 1). The muscle weight of the STZ group was 146 
significantly lower than that of the control group at 4 and 12 weeks. The relative muscle 147 
weight per body weight was also lower in the STZ group than in the control group, except for 148 
the SOL at 12 week (P=0.08).  149 
It has been shown that GLUT4 expression is greatly reduced in some conditions leading 150 
to muscle atrophy such as disuse 14), aging 15), denervation 16), and diabetes 17). In accordance 151 
with these studies, the GLUT4 levels in SOL and EDL muscles were reduced in the STZ 152 
group compared with the control group (Figure 1). 153 
 154 
Akt and p70S6K phosphorylation 155 
Akt Ser473 phosphorylation was significantly reduced in the SOL and EDL muscles of the 156 
STZ group at 12 weeks (Figure 2A). The change at 4 weeks was not statistical significant 157 
(Figure 2A). p70S6K is major substrate for mTOR, and the phosphorylation of p70S6K 158 
Thr389 in the STZ group was clearly reduced compared with that in the control group at both 159 
4 and 12 weeks (Figure 2B). 160 
 161 
Dystrophin mRNA and protein levels 162 
The dystrophin mRNA and protein levels were higher in the SOL of the STZ group than 163 
in the control group at both 4 and 12 weeks, and the mRNA and protein levels were also 164 
higher in the EDL of the STZ group than in the control group at 12 weeks (Figure 3A and 3B). 165 
A histochemical analysis showed marked fiber atrophy in the 12 weeks diabetic group 166 
compared with the control group (SOL, control = 4807 ± 275 μm2 vs. STZ = 2060 ± 106; 167 
 9 
EDL, control = 3305 ± 187 vs. STZ = 1144 ± 38, p<0.01, respectively; n = 4 per group), but 168 
dystrophin was expressed at the sarcolemma of all muscle fibers in the SOL and EDL muscles 169 
of the STZ and control groups at 12 weeks (Figure 3C).  170 
 10 
Discussion 171 
The STZ-induced diabetic animal model has often been used to study muscle atrophy in 172 
diabetes 9, 18, 19). We have shown for the first time that the dystrophin mRNA and protein 173 
levels are increased in the atrophic muscles of STZ-induced diabetic rats (Figure 3A), which 174 
are characterized by insulin-deficient hyperglycemia, low body weight, and low muscle 175 
weight (Table 1). Low muscle weight per body weight (Table 1) and a reduction in GLUT4 176 
levels (Figure 1) indicate that skeletal muscle atrophy was induced in our diabetic rats, 177 
because low GLUT4 expression is seen in some atrophic muscles including STZ-induced 178 
diabetes 14-17). Contrary to our findings, Mulvey et al. 20) reported that the expression of 179 
dystrophin is reduced in the skeletal muscles of type 2 diabetic Goto-Kakizaki rats. They 180 
speculated that the loss of dystrophin is at least partly responsible for the abnormal 181 
characteristics of the skeletal muscle in diabetes. However, their diabetic rats did not exhibit 182 
structural abnormalities, such as muscle atrophy. 183 
Although the exact function of dystrophin is not completely understood, it is known to 184 
play an important role in regulating the structural stability of the muscle cell membrane 1, 21). 185 
The signal transduction cascade from dystrophin has also been implicated in cell survival and 186 
defense mechanisms, and in the regulation of the balance between cell survival and cell death 187 
21, 22). There is also a functional link between dystrophin and cell growth signaling 10). It is 188 
noteworthy that dystrophin is elevated at the sarcolemma of cardiac myocytes in failing 189 
myocardium, and this is interpreted as a mechanism to preserve cellular stability and integrity 190 
23). Therefore, the increased expression of dystrophin might be a compensatory response that 191 
defend the muscle structure and functions against muscle atrophy under severely diabetic 192 
conditions. Further study is required to clarify the role of dystrophin upregulation in 193 
STZ-induced diabetes. 194 
Consistent with a previous study that demonstrated that Akt/mTOR signaling is 195 
 11 
associated with diabetic-induced muscle atrophy 9), we confirmed that Akt Ser473 and p70S6K 196 
Thr389 phosphorylation are reduced in atrophic muscles during diabetes (Figure 2). It has been 197 
demonstrated that the inactivation of mTOR leads to advanced myopathy, with a strong 198 
reduction in the muscle dystrophin content 10). However, we found that dystrophin levels were 199 
upregulated in the atrophic muscles of diabetic rats (Figure 3) although Akt/mTOR/p70S6K 200 
signaling was downregulated (Figure 2). This implies that the downregulation of mTOR 201 
signaling does not always cause a reduction in the dystrophin content of muscles. 202 
Taken together, our data suggest that a reduced dystrophin content is not a common 203 
feature of atrophic skeletal muscle, and that the pathogenesis of diabetic-induced muscle 204 
atrophy cannot be attributed to the downregulation of dystrophin levels. Other mechanisms 205 
such as the disturbance of protein synthesis signaling 9) and the increased expression of genes 206 
involved in protein degradation 24) may be crucial modulators of diabetic muscle atrophy.  207 
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Table 1. Body weight, plasma glucose concentration, muscle weight in control and 
STZ-induced diabetic rats. 
 Control  STZ 
Period (week) 0 4 12  0 4 12 
Body weight 
(g) 
191 ± 4 334 ± 8 531 ± 18  190 ± 4 280 ± 4 † 276 ± 4 † 
Plasma glucose 
(mg/dL) 
56 ± 2 76 ± 5 76 ± 3  70 ± 6 476 ± 22 † 490 ± 22 † 
SOL        
muscle weight 
(mg) 
― 140 ± 5 221 ± 4  ― 100 ± 4 † 107 ± 5 † 
weight/body 
weight 
― 0.42 ± 0.011 0.42 ± 0.016  ― 0.36 ± 0.010 * 0.38 ± 0.012 
EDL        
muscle weight 
(mg) 
― 154 ± 4 217 ± 6  ― 94 ± 10 † 87 ± 5 † 
weight/body 
weight 
― 0.46 ± 0.016 0.40 ± 0.016  ― 0.33 ± 0.024 † 0.32 ± 0.012 † 
number of 
animals 
14 4 10  12 3 9 
Values are mean ± SE. 282 
* P<0.05, † P<0.01 Significantly different from corresponding control group.  283 
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Figure legend 284 
Figure 1 285 
GLUT4 levels in SOL and EDL muscle. The muscle isolated from control and STZ groups 286 
was subjected to immunoblot analysis. Fold increases are expressed relative to the level of 287 
signal in the muscle of normal group (4 weeks). Equal protein loading and transfer was 288 
confirmed by Coomassie brilliant blue (CBB) staining of a 200-kDa protein. Representative 289 
immunoblots are shown. Values are mean ± SE. *P<0.05, †P<0.01 vs. corresponding control 290 
group. 291 
 292 
Figure 2 293 
Akt Ser473 phosphorylation (A), p70S6K Thr389 phosphorylation (B) levels in SOL and EDL 294 
muscle. The muscle isolated from control and STZ groups was subjected to immunoblot 295 
analysis. Fold increases are expressed relative to the level of signal in the muscle of normal 296 
group (4 weeks). Representative immunoblots are shown. Values are mean ± SE. *P<0.05, 297 
†P<0.01 vs. corresponding control group. 298 
 299 
Figure 3 300 
Dystrophin mRNA (A) and protein (B) levels in SOL and EDL muscle. The muscle isolated 301 
from control and STZ groups was subjected to real-time RT-PCR and immunoblot analysis. 302 
Fold increases are expressed relative to the levels in the muscle of normal group (4 weeks). 303 
Equal protein loading and transfer for immunoblot analysis was confirmed by CBB staining 304 
of a 200-kDa protein. Representative immunoblots are shown. Values are mean ± SE. *P<0.05, 305 
†P<0.01 vs. corresponding control group. Histochemical analysis of dystrophin localization 306 
(C). Representative transverse sections of SOL and EDL muscle dissected from 12-week 307 
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